×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KYTX – kyverna therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KYTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
06:54 am
kytx
Lupus Nephritis Dug Pipeline Landscape Report : Therapeutic Assessment by 2024 by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Low
Report
Lupus Nephritis Dug Pipeline Landscape Report : Therapeutic Assessment by 2024 by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/20
08:06 am
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $6.00. They now have a "neutral" rating on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $6.00. They now have a "neutral" rating on the stock.
11/17
08:19 am
kytx
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop [Yahoo! Finance]
Low
Report
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop [Yahoo! Finance]
11/15
03:26 pm
kytx
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $24.00. They now have an "overweight" rating on the stock.
Low
Report
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its price target lowered by analysts at Wells Fargo & Company from $44.00 to $24.00. They now have an "overweight" rating on the stock.
11/14
10:14 am
kytx
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]
Medium
Report
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]
11/14
10:01 am
kytx
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Low
Report
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
11/13
04:22 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/13
04:14 pm
kytx
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:14 pm
KYTX
kyverna therapeutics, inc.
MISS
Report
-7.0%
kyverna therapeutics, inc.
8/12/2024
04:08 pm
KYTX
kyverna therapeutics, inc.
BEAT
Report
5.1%
kyverna therapeutics, inc.
8/12/2024
04:08 pm
KYTX
kyverna therapeutics, inc.
BEAT
Report
5.1%
kyverna therapeutics, inc.
8/12/2024
04:08 pm
KYTX
kyverna therapeutics, inc.
BEAT
Report
4.2%
kyverna therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
04:25 pm
kytx
Form 10-Q Kyverna Therapeutics, For: Sep 30
High
Report
Form 10-Q Kyverna Therapeutics, For: Sep 30
11/13
04:16 pm
kytx
Form 8-K Kyverna Therapeutics, For: Nov 08
High
Report
Form 8-K Kyverna Therapeutics, For: Nov 08
11/12
09:24 am
kytx
Form SC 13G Kyverna Therapeutics, Filed by: Westlake BioPartners Fund I, L.P.
Medium
Report
Form SC 13G Kyverna Therapeutics, Filed by: Westlake BioPartners Fund I, L.P.
10/24
06:06 am
kytx
Form 4 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
Low
Report
Form 4 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
10/24
06:03 am
kytx
Form 3 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
Low
Report
Form 3 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
10/21
08:01 am
kytx
Form 8-K Kyverna Therapeutics, For: Oct 20
Medium
Report
Form 8-K Kyverna Therapeutics, For: Oct 20
10/10
12:37 pm
kytx
Form SC 13G Kyverna Therapeutics, Filed by: JPMORGAN CHASE & CO
Low
Report
Form SC 13G Kyverna Therapeutics, Filed by: JPMORGAN CHASE & CO
9/18
09:19 pm
kytx
Form 4 Kyverna Therapeutics, For: Sep 16 Filed by: Biddle Warner Weston
Medium
Report
Form 4 Kyverna Therapeutics, For: Sep 16 Filed by: Biddle Warner Weston
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: